These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 10947539)

  • 1. Promising pharmacological agents in the management of acute spinal cord injury.
    Seidl EC
    Pharm Pract Manag Q; 2000 Apr; 20(1):21-7. PubMed ID: 10947539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promising pharmacological agents in the management of acute spinal cord injury.
    Seidl EC
    Crit Care Nurs Q; 1999 Aug; 22(2):44-50. PubMed ID: 10646442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical applications of pharmacologic therapies for spinal cord injury.
    Zeidman SM; Ling GS; Ducker TB; Ellenbogen RG
    J Spinal Disord; 1996 Oct; 9(5):367-80. PubMed ID: 8938604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological management of acute spinal cord injury.
    Sharma A
    J Assoc Physicians India; 2012 May; 60 Suppl():13-8. PubMed ID: 23155791
    [No Abstract]   [Full Text] [Related]  

  • 5. New drugs for improving injury outcome in spinal cord injuries.
    Werner PC
    West J Med; 1997 Apr; 166(4):271-2. PubMed ID: 9168687
    [No Abstract]   [Full Text] [Related]  

  • 6. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial.
    Bracken MB; Shepard MJ; Holford TR; Leo-Summers L; Aldrich EF; Fazl M; Fehlings MG; Herr DL; Hitchon PW; Marshall LF; Nockels RP; Pascale V; Perot PL; Piepmeier J; Sonntag VK; Wagner F; Wilberger JE; Winn HR; Young W
    J Neurosurg; 1998 Nov; 89(5):699-706. PubMed ID: 9817404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study.
    Bracken MB; Shepard MJ; Holford TR; Leo-Summers L; Aldrich EF; Fazl M; Fehlings M; Herr DL; Hitchon PW; Marshall LF; Nockels RP; Pascale V; Perot PL; Piepmeier J; Sonntag VK; Wagner F; Wilberger JE; Winn HR; Young W
    JAMA; 1997 May; 277(20):1597-604. PubMed ID: 9168289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological therapy for acute spinal cord injury.
    Hurlbert RJ; Hadley MN; Walters BC; Aarabi B; Dhall SS; Gelb DE; Rozzelle CJ; Ryken TC; Theodore N
    Neurosurgery; 2015 Mar; 76 Suppl 1():S71-83. PubMed ID: 25692371
    [No Abstract]   [Full Text] [Related]  

  • 9. Lack of effect of postinjury treatment with methylprednisolone or tirilazad mesylate on the increase in eicosanoid levels in the acutely injured cat spinal cord.
    Hall ED; Yonkers PA; Taylor BM; Sun FF
    J Neurotrauma; 1995 Jun; 12(3):245-56. PubMed ID: 7473799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trials of pharmacotherapy for spinal cord injury.
    Geisler FH
    Ann N Y Acad Sci; 1998 Jun; 845():374-81. PubMed ID: 9668370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug development in spinal cord injury: what is the FDA looking for?
    Hall ED
    J Rehabil Res Dev; 2003; 40(4 Suppl 1):81-91. PubMed ID: 15077652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological treatment of acute spinal cord injury: how do we build on past success?
    Hall ED
    J Spinal Cord Med; 2001; 24(3):142-6. PubMed ID: 11585231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Methylprednisolone in the treatment of acute spinal cord injury has become more and more questioned].
    Kronvall E; Sayer FT; Nilsson OG
    Lakartidningen; 2005 Jun 13-26; 102(24-25):1887-8, 1890. PubMed ID: 16044768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study.
    Bracken MB; Shepard MJ; Collins WF; Holford TR; Young W; Baskin DS; Eisenberg HM; Flamm E; Leo-Summers L; Maroon J
    N Engl J Med; 1990 May; 322(20):1405-11. PubMed ID: 2278545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylprednisolone in acute spinal cord injury: a tarnished standard.
    Miller SM
    J Neurosurg Anesthesiol; 2008 Apr; 20(2):140-2. PubMed ID: 18362778
    [No Abstract]   [Full Text] [Related]  

  • 16. Acute spinal cord injury: pharmacotherapy and drug development perspectives.
    Blight AR; Zimber MP
    Curr Opin Investig Drugs; 2001 Jun; 2(6):801-8. PubMed ID: 11572660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Summary statement: the Sygen(GM-1 ganglioside) clinical trial in acute spinal cord injury.
    Fehlings MG; Bracken MB
    Spine (Phila Pa 1976); 2001 Dec; 26(24 Suppl):S99-100. PubMed ID: 11805615
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of acute injury of the cervical spine.
    Slucky AV; Eismont FJ
    Instr Course Lect; 1995; 44():67-80. PubMed ID: 7797894
    [No Abstract]   [Full Text] [Related]  

  • 19. GM-1 ganglioside and motor recovery following human spinal cord injury.
    Geisler FH
    J Emerg Med; 1993; 11 Suppl 1():49-55. PubMed ID: 8445203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on pharmaceutical trials in acute spinal cord injury.
    Lammertse DP
    J Spinal Cord Med; 2004; 27(4):319-25. PubMed ID: 15484662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.